The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2024 | How to approach the treatment of elderly/unfit patients with Hodgkin lymphoma
Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, discusses how to approach the treatment of elderly or unfit patients with Hodgkin lymphoma (HL). Dr Ansell highlights that the use of the AVD chemotherapy regimen (doxorubicin, vinblastine, and dacarbazine) with either nivolumab or brentuximab vedotin is the preferred therapeutic strategy, providing that the patient’s fitness is appropriate. In very frail patients, a single-agent approach may be more feasible to provide a degree of disease control. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
